Nanoparticulate Drug Delivery to the Retina
The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Abstract
Retinal diseases, such as age-related macular degeneration and diabetic retinopathy, are the leading causes of blindness worldwide. The mainstay of treatment for these blinding diseases remains to be surgery, and the available pharmaceutical therapies on the market are limited, partially owing to various biological barriers in hindering the delivery of therapeutics to the retina. The nanoparticulate drug delivery system confers the capability for delivering therapeutics to the specific ocular targets and, hence, potentially revolutionizes the current treatment landscape of retinal diseases. While the research to date indicates the enormous therapeutics potentials of the nanoparticulate delivery systems, the successful translation of these systems from the bench to bedside is challenging and requires a combined understanding of retinal pathology, physiology of the eye, and particle and formulation designs of nanoparticles. To this end, the review begins with an overview of the most prevalent retinal diseases and related pharmacotherapy. Highlights of the current challenges encountered in ocular drug delivery for each administration route are provided, followed by critical appraisal of various nanoparticulate drug delivery systems for the retinal diseases, including their formulation designs, therapeutic merits, limitations, and future direction. It is believed that a greater understanding of the nano-biointeraction in eyes will lead to the development of more sophisticated dru…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Polymer nanoparticles: Preparation techniques and size-control parameters
Rao, J. P., & Geckeler, K. E. (2011) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2011.01.001 · Cited by 1,725
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Dendrimer biocompatibility and toxicity
DUNCAN, R., & IZZO, L. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.019 · Cited by 1,158
Amphiphilic block copolymers for drug delivery
Adams, M. L., Lavasanifar, A., & Kwon, G. S. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10397 · Cited by 1,078
International Journal of Ophthalmology
(2020) · International Journal of Ophthalmology · doi:10.18240/ijo · Cited by 597
Diabetic Retinopathy: Vascular and Inflammatory Disease
Semeraro, F., Cancarini, A., dell’Omo, R., Rezzola, S., Romano, M. R., & Costagliola, C. (2015) · Journal of Diabetes Research · doi:10.1155/2015/582060 · Cited by 424
Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences
Pastor, J. C., Rojas, J., Pastor-Idoate, S., Di Lauro, S., Gonzalez-Buendia, L., & Delgado-Tirado, S. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.07.005 · Cited by 344
Drug delivery to the posterior segment of the eye
Thrimawithana, T. R., Young, S., Bunt, C. R., Green, C., & Alany, R. G. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.12.004 · Cited by 335
Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo
Xu, Q., Boylan, N. J., Suk, J. S., Wang, Y.-Y., Nance, E. A., Yang, J.-C., McDonnell, P. J., Cone, R. A., Duh, E. J., & Hanes, J. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.018 · Cited by 326
Nanomedicines for back of the eye drug delivery, gene delivery, and imaging
Kompella, U. B., Amrite, A. C., Pacha Ravi, R., & Durazo, S. A. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.04.001 · Cited by 258
Research works printed but not linked: 9
- 10.18043/ncm.78.2.124 · DOI
- Moraru A. D., 2014, Rom j Morphol Embryol., 55, 869
- Spitznas M., 1974, Adv. Ophthalmol., 28, 78
- Bochot A., 2002, Invest Ophthalmol Vis Sci., 43, 253
- Fiscella R., 1987, Can. J. Ophthalmol., 22, 307
- Rahman M., 2012, Polyester
- 10.1016/j.jconrel.2012.12.005 · DOI · Paper page
- Su D. H., 2006, Invest. Ophthalmol. Vis. Sci., 47, 5122
- Cai X., 2016, Mol. Vis., 22, 1176
Cited by
Nguyen, D. D., Luo, L.-J., Yang, C.-J., & Lai, J.-Y. (2023) · ACS Nano · doi:10.1021/acsnano.2c05824 · Cited by 213
Nanoparticles in ocular applications and their potential toxicity
Cao, Y., Yang, J., Lu, A., Gong, J., Yang, Y., Lin, X., Li, M., & Xu, H. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.931759 · Cited by 119
Hyaluronic acid-based nanoparticles to deliver drugs to the ocular posterior segment
Jiang, H., & Xu, Z. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2204206 · Cited by 68
“Due to their splendid stability and wide drug loading range, micelles modified with HA have been widely investigated for tumor therapy (W. Li et al., 2020; Zhang, Ren et al., 2020; Yan, Feng et al., 2022).”
BackgroundGreen Light‐Triggered Intraocular Drug Release for Intravenous Chemotherapy of Retinoblastoma
Long, K., Yang, Y., Lv, W., Jiang, K., Li, Y., Lo, A., Lam, W., Zhan, C., & Wang, W. (2021) · Advanced Science · doi:10.1002/advs.202101754 · Cited by 63
Vesicular Drug Delivery Systems: Promising Approaches in Ocular Drug Delivery
Batur, E., Özdemir, S., Durgun, M. E., & Özsoy, Y. (2024) · Pharmaceuticals · doi:10.3390/ph17040511 · Cited by 74
“These obstacles need to be cleared before liposomes are applied topically [39].”
BackgroundInfluentialWu, K. Y., Joly-Chevrier, M., Akbar, D., & Tran, S. D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041094 · Cited by 55
Chan, H. W., Chow, S., Zhang, X., Kwok, P. C. L., & Chow, S. F. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.07.002 · Cited by 48
Self-citationTopical drug delivery to the retina: obstacles and routes to success
Loftsson, Þ. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2017878 · Cited by 44
“Most frequently they are stabilized by a mixture of surfactants, some of which can act as chemical penetration enhancers by decreasing the barrier of the lipophilic membranes [9,122].”
BackgroundOcular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina
Wang, L., & Zhang, H. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01231-5 · Cited by 44
Topical drug delivery to the posterior segment of the eye: Thermodynamic considerations
Sripetch, S., & Loftsson, Þ. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120332 · Cited by 41
Recent advances in engineered exosome-based therapies for ocular vascular disease
Guan, J., Meng, F., Wang, C., Zhang, B., Chen, J., & Han, J. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03589-3 · Cited by 36
“Owing to their small size and diverse surface properties, exosomes are not only utilized for targeted drug delivery but also for modulating disease mechanisms, promoting tissue repair, and enhancing therapeutic outcomes in neo-vascular ocular diseases [36–38].”
Metallic Engineered Nanomaterials and Ocular Toxicity: A Current Perspective
Cosert, K. M., Kim, S.-H., Jalilian, I., Chang, M., Gates, B. L., Pinkerton, K. E., Winkle, L. S. V., Raghunathan, V. K., Leonard, B. C., & Thomasy, S. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050981 · Cited by 32
Dasatinib loaded nanostructured lipid carriers for effective treatment of corneal neovascularization
Li, Q., Yang, X., Zhang, P., Mo, F., Si, P., Kang, X., Wang, M., & Zhang, J. (2021) · Biomaterials Science · doi:10.1039/d0bm01599g · Cited by 32
Self-citationDubashynskaya, N. V., Bokatyi, A. N., Головкин, А. С., Kudryavtsev, I. V., Serebryakova, M. K., Trulioff, A. S., Dubrovskii, Y. A., & Skorik, Y. А. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010960 · Cited by 31
“The use of various nanoparticles for retinal delivery does not ensure the desired months-long release profile and can also lead to increased intraocular pressure and visual impairment [11].”
BackgroundNiu, T., Shi, X., Liu, X., Wang, H., Liu, K., & Xu, Y. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00785-z · Cited by 30
Natural products for the treatment of age-related macular degeneration
Wang, D., Chen, Y., Li, J., Wu, E., Tang, T., Singla, R. K., Shen, B., & Zhang, M. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155522 · Cited by 32
Fluorescent Nanosystems for Drug Tracking and Theranostics: Recent Applications in the Ocular Field
Zingale, E., Romeo, A., Rizzo, S., Cimino, C., Bonaccorso, A., Carbone, C., Musumeci, T., & Pignatello, R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050955 · Cited by 32
Trends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye
Biswas, A., Choudhury, A. D., Bisen, A. C., Agrawal, S., Sanap, S. N., Verma, S. K., Mishra, A., Kumar, S., & Bhatta, R. S. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02673-x · Cited by 31
“…naturally and undergo in vivo metabolism; (5) certain properties, such as cell porosity, can be somewhat modified; [82] and (6) various sorts of solvents with various properties and particle sizes, such as compounds that are soluble in lipids, water, or both, can be included in liposomes [83].”
BackgroundBohley, M., Dillinger, A. E., Tamm, E. R., & Göpferich, A. M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.05.024 · Cited by 29
Ruiz, E. A. C., Swindle‐Reilly, K. E., & Versypt, A. N. F. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.021 · Cited by 29
Advances in biomaterials for the treatment of retinoblastoma
Farhat, W., Yeung, V., Ross, A., Kahale, F., Boychev, N., Kuang, L., Chen, L., & Ciolino, J. B. (2022) · Biomaterials Science · doi:10.1039/d2bm01005d · Cited by 29
Chen, K.-S., Chan, H.-C., & Chan, C.-M. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10884-x · Cited by 30
“This targeted approach can mitigate systemic side effects and boost local therapeutic concentrations in diseases such as AMD and diabetic retinopathy [142].”
Bohley, M., Dillinger, A. E., Schweda, F., Ohlmann, A., Braunger, B. M., Tamm, E. R., & Göpferich, A. M. (2022) · Science Advances · doi:10.1126/sciadv.abo6638 · Cited by 23
“1) ( 23 , 24 ).”
Huang, Y., Lü, J., Zhao, L., Fu, X., Peng, S., Zhang, W., Wang, R., Yuan, W., Luo, R., Wang, X., et al. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.06.024 · Cited by 21
Novel Drug Delivery Methods and Approaches for the Treatment of Retinal Diseases
Ham, Y., Mehta, H., Kang‐Mieler, J. J., Mieler, W. F., & Chang, A. (2023) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000623 · Cited by 25
Smart Nanocarriers for the Treatment of Retinal Diseases
Liu, S., Yan, Z., Huang, Z., Yang, H., & Li, J. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c01289 · Cited by 16
ROS-Responsive Nanoparticles with Antioxidative Effect for the treatment of Diabetic Retinopathy
Li, J., Liu, Y., Geng, K., Lu, X., Shen, X., & Guo, Q. (2024) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2024.2406628 · Cited by 18
“In contrast, nanoparticles show potential in enhancing the cellular uptake of hydrophobic drugs [15].”
Zhang, X., Chau, L. Y., Chan, H. W., Weng, J., Wong, K. W., Chow, S. F., & Chow, A. H. L. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120224 · Cited by 16
Self-citationMicrobubble-Assisted Ultrasound for Drug Delivery to the Retina in an Ex Vivo Eye Model
Rousou, C., van Kronenburg, N. C. H., Sonnen, A. F. ‐., van Dijk, M. R., MOONEN, C. T. W., Storm, G., Mastrobattista, E., & Deckers, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041220 · Cited by 15
Annexin A1 in the nervous and ocular systems
Wang, A., Zhang, H., Li, X., & Zhao, Y. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.380882 · Cited by 13
“Gold and silver NPs have enabled the treatment of neovascular retinal diseases; and, nanowires and hybrid nanostructures, together with stem cell transplantation techniques, have boosted retinal regeneration (Sharma et al., 2021).”
BackgroundInfluentialThe role of lipid metabolism disorder in the progression and treatment of ocular vascular diseases
Song, W., Chen, W., Chi, J., Liu, X., & Zhu, W. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.09.002 · Cited by 12
Localization of fluorescent gold nanoparticles throughout the eye after topical administration
Raîche-Marcoux, G., Méthot, S. J., Tchatchouang, A., Bettoli, C., Maranda, C., Loiseau, A., Proulx, S., Rochette, P. J., Génin, E., & Boisselier, É. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1557611 · Cited by 9
Nanomedicine in ophthalmology: conquering anatomical barriers and enhancing therapeutic efficacy
Wang, T., Wang, Y., Li, S., Wang, Y., & Lan, X. (2026) · Biomaterials Science · doi:10.1039/d5bm00325c · Cited by 9
Polymer–lipid hybrid nanostructures for drug delivery
Gusmão, L. A., & Tedesco, A. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85754-3.00003-4 · Cited by 10
From design to Deployment: The innovative role of nanomicelles in targeted ophthalmic therapeutics
Sun, M., Wang, J., Fan, W., Wang, K., Wang, Y., Zhang, J., Ding, S., Zhang, C., Feng, Z., Wang, Y.-G., et al. (2025) · Materials today. Bio · doi:10.1016/j.mtbio.2025.102537 · Cited by 7
“It has been reported that at least 10 % of sodium fluorescein is eliminated through the lymphatics within 1 h following administration in the subconjunctival space [28].”
Liu, J., Zhang, F., & Shi, X. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139017 · Cited by 9
Peynshaert, K., Devoldere, J., Smedt, S. C. D., & Remaut, K. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2167979 · Cited by 7
“Considering that the bulk of NPs for retinal gene therapy are studied with IVT administration in mind and this route is associated with multiple drug delivery barriers, we will mainly discuss nano delivery via IVT injection as a case study for this section[85].”
BackgroundBi, X., Deng, Y., Chu, C., Wei, M., Zhao, J., Zhao, J., Wang, Y., Yin, T., Gou, J., He, H., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125543 · Cited by 6
Emerging Nanomedicine Strategies for Chronic Disease Management Based on Chitosan
Pacheco, Y. P., Parajuli, D., & Garcia‐Valls, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031387 · Cited by 6
“Treatment effectiveness is often limited by anatomical and physiological barriers including resultant injuries, corneal permeability, and poor drug retention on the ocular surface, presenting significant challenges for topical therapies [17].”
Nordin, N. A., Sadikan, M. Z., Lambuk, L., Hashim, S., Airuddin, S., Nasir, N. A. M., Mohamud, R., Ibrahim, J., & Kadir, R. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae129 · Cited by 7
Ji, R., Ishikawa, K., Tan, W., Mori, K., Tsukamoto, R., Matsunaga, N., Kiyohara, K., Fukuda, Y., Wada, I., Isobe, T., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.6.56 · Cited by 5
“27,28 35 In this study, we aimed to investigate the potential of liposome-encapsulated ripasudil (Lipo-Ripa) in alleviating intraocular fibrosis, which can pave the way to a new era in the therapeutic management of PVR and nAMD.”
An update on the latest strategies in retinal drug delivery
Ranch, K. M., Chawnani, D., Jani, H., Acharya, D., Patel, C. A., Jacob, S., Babu, R. J., Tiwari, A. K., Al-Tabakha, M. M., & Boddu, S. H. S. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2358886 · Cited by 5
“While there is ample evidence in support of therapeutic potential of polymeric nanoparticles, translating them from bench to the bedside requires a greater understanding of the nano-biointeraction in eyes [81].”
BackgroundJiao, X., Peng, X., Jin, X., Liu, N., Yu, Y., Liu, R., & Li, Z. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01376-x · Cited by 4
“The development of nanotechnology could deliver drugs to the site of action with ideal route [13].”
BackgroundXu, L., Chen, Z.-A., Wu, C.-H., Chen, Y., Wu, S., Mou, C., Tseng, C., Chien, Y., Chan, H. W.-H., Yang, T., et al. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107398 · Cited by 3
Gu, S.-S., Xia, L.-X., Li, Y.-P., Chen, J., Wu, Y.-N., Cui, Y., Huang, H.-J., Meng, J., Mei, Q., & Pan, H. (2026) · Biomaterials Science · doi:10.1039/d6bm00015k · Cited by 2
Figueiredo, I., Bicker, J., Vitorino, C., & Fortuna, A. C. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2668677 · Cited by 2
“In a study conducted by Ghazwani et minutes after intranasal administration of a sertraline-loaded thermoreversible gel, the brain-to-plasma ratio was twice of that observed with IV or oral routes, indicating a prolonged and sustained brain delivery [54].”
Li, S., Zhang, F., Tao, Y., Du, X., & Sun, Z. (2021) · Science of Advanced Materials · doi:10.1166/sam.2021.4037 · Cited by 2
ROS-Responsive Nanoparticles with Antioxidative Effect for the treatment of Diabetic RetinopathyPreprint
Liu, Y., Li, J., Geng, K., Lu, X., Shen, X., & Guo, Q. (2024) · Research Square · doi:10.21203/rs.3.rs-4134272/v1 · Cited by 2
Li, J., Wang, T., Chen, H., Zhou, X., & Wang, S. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.115367 · Cited by 1
Polymerization‐Induced Self‐Assembly of Nonlinear Polymers
Wang, R., Zhang, L., & Tan, J. (2026) · Chemistry - A European Journal · doi:10.1002/chem.70945 · Cited by 1
Nanocarrier-Based Ocular Drug Delivery Systems for Retinal Diseases: Therapeutic Potential
Skarbek, D., Sochocka, A., Sidło, O., Sapiaszko, A., Drab, A., Baj, J., Ręjdak, R., & Dolar-Szczasny, J. (2026) · Life · doi:10.3390/life16050810 · Cited by 1
“Functionalization strategies, such as ligand conjugation or surface modification with targeting moieties, have been shown to improve delivery efficiency [32,45–47].”
Mehta, P., Moore, E. D., Dash, A. K., & Shukla, S. (2026) · Cells · doi:10.3390/cells15171534 · Cited by 1
“It is critically important to recognize that conventional topical delivery reaches as little as 5% of the applied dose at the retina [107].”
Nanoparticles as Cell Tracking Agents in Human Ocular Cell Transplantation Therapy
Mundy, D. C., & Goldberg, J. L. (2021) · Current Ophthalmology Reports · doi:10.1007/s40135-021-00275-z · Cited by 1
Nanotechnologies to deliver drugs through the blood–brain and blood–retinal barriers
Costa, M. C., Shegokar, R., Silva, A. M., & Souto, E. B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90471-1.00010-4 · Cited by 1
Safety and Toxicities of Nanocarriers in Ophthalmic Drug Delivery System
Kadiri, S. K., Iswariya, V. T., Tiwari, P. K., & Rajesham, V. V. (2025) · Springer eBooks · doi:10.1007/978-981-96-6306-4_10 · Cited by 4
Niu, T., Shi, X., Liu, X., Wang, H., Liu, K., & Xu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25157317
Niu, T., Shi, X., Liu, X., Wang, H., Liu, K., & Xu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25157825
Menna, F., Pinelli, C., Luca, L. D., Meduri, A., Baldascino, A., Lupo, S., & Vingolo, E. M. (2026) · Biomedicines · doi:10.3390/biomedicines14040782
Dias, M. F., Silva‐Cunha, A., & Fialho, S. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36643-7.00005-6
Metadata
- Authors
- Li, Q., Weng, J., Wong, S. N., Thomas Lee, W. Y., & Chow, S. F.
- Affiliations
- Xi'an Jiaotong University (CN)
- University of Hong Kong (HK)
- Aptorum Group Limited, Unit 232, 12 Science Park West Avenue, Hong Kong Science Park, Shatin New Town, Hong Kong
- Corresponding author
- Chow, Shing Fung
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-06-08
- Volume
- 18
- Issue
- 2
- Pages
- 506-521
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W3033428304
- Cited by
- 59
- References
- 153
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 11 · 2023: 12 · 2022: 9 · 2021: 8
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Hong Kong (202007002)
- Natural Science Foundation of Shaanxi Province (2020JQ-093)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- nanoparticle drug delivery, retinal drug delivery, ocular drug delivery, age-related macular degeneration, diabetic retinopathy, retinal disease, ocular barriers, translation to clinical practice
- MeSH terms
- Administration, Oral, Animals, Blindness, Blood-Retinal Barrier, Choroid, Conjunctiva, Cornea, Disease Models, Animal, Humans, Ophthalmic Solutions, Permeability, Retina, Retinal Diseases, Sclera, Nanoparticles, Administration, Ophthalmic, Administration, Intravenous, Drug Liberation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.